“I really want to go to your performance,” my husband, Todd, told our daughter, Sara, who was starting a weeklong intensive with Eisenhower Dance Detroit that will culminate in a performance Saturday. “It’s just too hard to get out, and I don’t want to sit in the theater with…
A man with amyotrophic lateral sclerosis (ALS) implanted with Synchron‘s brain-computer interface was the first person in the world to use his thoughts to control an Apple Vision Pro. Using the investigational brain-computer interface, or BCI, the 64-year-old man, who’d lost function in his upper limbs due to ALS,…
The biotechnology company Revir Therapeutics has raised $30 million in funding to advance the development of oral genetic therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. This Series A financing was led by the healthcare-focused venture capital firm Lapam Capital. Revir will use the proceeds to…
Copying someone’s actions can be fun and help us learn new things. But imitation can also be dangerous, especially if you live with a serious condition such as ALS, which I have. I learned a lesson in imitation many years ago, while I was teaching a class in aerobic…
Twelve years ago, my husband, Todd, and I installed bamboo flooring in three bedrooms and the living room of our new accessible home. Todd had been diagnosed with ALS two years before, and his arms had become quite weak. Contractors built most of the house, and a few volunteers…
Imagine you’re all alone, stranded on a remote island and surrounded by miles and miles of uncharted ocean. Here’s my question: How much time would you let pass before giving up hope of ever being rescued? One year? How about five years? Or are you an “I’ll never give up…
Io Therapeutics is planning to launch a Phase 2 trial into its investigational oral therapy IRX4204 in people with amyotrophic lateral sclerosis (ALS). The decision follows recent tests showing that the candidate treatment dampened neuroinflammation in an animal model of neuronal autoimmunity, or diseases marked by self-directed…
Repeat infusions of naive immune B-cells were safe and delayed disease onset, reduced disease severity, and extended survival in animal models of amyotrophic lateral sclerosis (ALS), a study found. The approach was also deemed safe in the treatment’s first in-human case study, in which it eased disease severity and…
People with amyotrophic lateral sclerosis (ALS) who received one year of treatment with PrimeC, an experimental oral tablet from NeuroSense Therapeutics, lived significantly longer without disease complications and had a slower lung function decline than those who started treatment six months later. That’s according to the latest results…
Clene said it planned to give the U.S. Food and Drug Administration (FDA) new data on CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS) ahead of a meeting on a path to accelerated approval of the therapy. The company said it would submit a briefing book…
